Authors state that a post-hoc analysis suggested that rasagiline might modify disease progression in patients with an initial slope of Amyotrophic Lateral Sclerosis Functional Rating Scale Revised >0ยท5 points per month at baseline, but that this is exploratory only and requires confirmation in further research.
A related commentary discusses this study. It suggests that although this placebo controlled trial was negative for all of the pre-specified primary and secondary outcomes, the post-hoc analyses provide valuable data that can be used for planning cohort enrichment strategies in future clinical trials of patients with amyotrophic lateral sclerosis.